On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback